BioNTech on track for a catalyst-rich year with six late-stage data readouts expected across immunomodulators, antibody-drug conjugates and mRNA cancer immunotherapies Increased focus on PD-L1 1 /VEGF ...

Yes, you can earn over $100K a year without ever stepping foot in a cubicle again.

How to make a CV with AI: In today's world, a clean and well-crafted resume is essential for securing a job. Resumes are the first document companies look at to form their first opinion about a ...

The world’s largest offshore wind farm, the Dogger Bank Wind Farm, started producing electricity in 2023. It is now seeing its phase B entering the commercial stage in early 2026, with phase C to ...

The 2025/26 La Liga season is heating up and while the Premier League stole the headlines this summer, Spain’s biggest clubs have quietly made some serious moves! In this video, we break down the ...

LAS VEGAS, March 10, 2026 /PRNewswire/ -- BOXABL Inc. ("BOXABL"), the innovative technology construction company on a mission to solve the global housing crisis, today announced the appointment of ...

Decentralized autonomous organization principles can be used to reimagine work platform governance, shifting from centralized ...

AI is rapidly transforming education, creating as much uncertainty as opportunity. Faculty, parents, and students share anxiety about AI, and yet, students are using AI every day, often without ...

Pepeto just announced an AI powered market protection system designed by the former Binance executive on the advisory board, and the crypto news around this Pepeto development is accelerating because ...

When Jensen Huang stood on stage and declared that the world's data centers are being "reinvented as AI factories," he crystallized something the industry had been circling for years. NVIDIA's vision ...

BioNTech on track for a catalyst-rich year with six late-stage data readouts expected across immunomodulators, antibody-drug conjugates and mRNA ...

First Patient Enrolled in RETAIN Phase 2/3 Registration Trial of PLG0206, a First-in-Class Anti-Biofilm Drug Initially Targeting Prosthetic Joint Infection “RETAIN is a landmark trial that will ...